相关实验视频

Updated: Jan 18, 2026

Novel Passive Clearing Methods for the Rapid Production of Optical Transparency in Whole CNS Tissue

Novel Passive Clearing Methods for the Rapid Production of Optical Transparency in Whole CNS Tissue

Published on: May 8, 2018

向的ErbB4受体激活可以通过DOCK3信号在转基因小鼠AD模型中改善神经元缺陷

Chong Liu¹, Yan Zhao², Ji-Ji Dao¹

¹MOE Medical Basic Research Innovation Center for Gut Microbiota and Chronic Diseases, Department of Cell Biology, Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, China.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

|September 12, 2025

概括

用E4A对ErbB4受体的向激活在阿尔茨海默病 (AD) 鼠标模型中改善了认知缺陷. 这种治疗通过增强DOCK3信号传递来减少神经炎症和粉样质斑块,提供了潜在的AD疗法.

科学领域:

神经科学是一个神经科学.
药理学药理学是指药理学的学科.
分子生物学分子生物学

背景情况:

阿尔茨海默病 (AD) 涉及ErbB4受体功能障碍.
现有的阿尔茨海默病治疗方法有局限性.

研究的目的:

为了研究ErbB4受体激活在AD中的治疗潜力.
阐明AD模型中E4A治疗背后的分子机制.

主要方法:

在APP/PS1小鼠模型中使用小分子ErbB4激动剂 (E4A).
评估认知行为,突触和线粒体功能以及神经炎症标志物.
进行了涉及微质细胞和DOCK3沉默的体外研究.

主要成果:

在APP/PS1小鼠中,E4A治疗显著改善了认知缺陷.
E4A增强了DOCK3和SIRT3的表达,改善了突触和线粒体功能.
E4A减弱TLR4-NF-κB-NLRP3通路的激活,减少神经炎症和β-粉样斑块.
在体外,E4A减轻了微质炎症,部分依赖DOCK3.

结论:

用E4A对ErbB4的有针对性的激活显示出对阿尔茨海默病的治疗有希望.
该机制涉及DOCK3信号传递,抑制神经元损伤,并减少神经炎症.

关键词:

阿尔茨海默病 (AD) 是一种疾病.在 DOCK3 中使用 DOCK3.对于ErbB4受体来说,这是一个很好的选择.小分子激动剂小分子激动剂突触突触是一个突触突触.

更多相关视频

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

Stereotaxic Infusion of Oligomeric Amyloid-beta into the Mouse Hippocampus

Stereotaxic Infusion of Oligomeric Amyloid-beta into the Mouse Hippocampus

Published on: June 17, 2015

相关概念视频

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Enzyme-linked Receptors

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...